Related Experiment Video
Updated: Aug 13, 2025
Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
The 4-Aminomethylphenoxy-Benzoxaborole AN3057 as a Potential Treatment Option for Primary Amoebic Meningoencephalitis
Kateřina Ženíšková1, Jan Mach1, Dominik Arbon1
1Department of Parasitology, Faculty of Science, Charles University, BIOCEV, Vestec, Czech Republic.
Abstract:
Primary amoebic meningoencephalitis is a rare but fatal central nervous system (CNS) disease caused by the "brain-eating amoeba" Naegleria fowleri. A major obstacle is the requirement for drugs with the ability to cross the blood-brain barrier, which are used in extremely high doses, cause severe side effects, and are usually ineffective. We discovered that the 4-aminomethylphenoxy-benzoxaborole AN3057 exhibits nanomolar potency against N. fowleri, and experimental treatment of infected mice significantly prolonged survival and demonstrated a 28% relapse-free cure rate.
Insights
A new drug, AN3057, shows promise in treating primary amoebic meningoencephalitis, a deadly brain infection caused by the Naegleria fowleri amoeba. This compound effectively treated infected mice, offering hope for a new therapeutic approach.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- Primary amoebic meningoencephalitis (PAM) is a rare, fatal infection of the central nervous system (CNS).
- It is caused by the pathogenic amoeba Naegleria fowleri.
- Current treatments face challenges due to poor blood-brain barrier penetration, high toxicity, and limited efficacy.
Purpose of the Study:
- To evaluate the efficacy of the novel benzoxaborole compound AN3057 against Naegleria fowleri.
- To assess the therapeutic potential of AN3057 in a murine model of primary amoebic meningoencephalitis.
Main Methods:
- In vitro assessment of AN3057 potency against Naegleria fowleri.
- In vivo experimental treatment of PAM-infected mice with AN3057.
- Monitoring of survival rates and relapse-free cure rates in treated mice.
Main Results:
- AN3057 demonstrated nanomolar potency against Naegleria fowleri in vitro.
- Experimental treatment with AN3057 significantly prolonged survival in infected mice.
- A 28% relapse-free cure rate was observed in the treated mouse cohort.
Conclusions:
- The benzoxaborole AN3057 is a potent inhibitor of Naegleria fowleri.
- AN3057 shows therapeutic potential for treating primary amoebic meningoencephalitis.
- Further investigation into AN3057 as a treatment for PAM is warranted.
More Related Videos
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
11:01Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
Published on: November 23, 2016
